Experimenteel medicijn verdubbelt bijna overlevingsduur bij gevorderde alvleesklierkanker

Researchers have demonstrated that an experimental medication called daraxonrasib significantly extends survival for patients with advanced pancreatic cancer by targeting a mutated protein present in over 90% of cases. While the drug does not cure the disease, medical experts describe it as a major breakthrough for treating one of cancer's most aggressive forms.